These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 28535817)

  • 1. Safety and tolerability of autologous bone marrow mesenchymal stromal cells in ADPKD patients.
    Makhlough A; Shekarchian S; Moghadasali R; Einollahi B; Hosseini SE; Jaroughi N; Bolurieh T; Baharvand H; Aghdami N
    Stem Cell Res Ther; 2017 May; 8(1):116. PubMed ID: 28535817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone marrow-mesenchymal stromal cell infusion in patients with chronic kidney disease: A safety study with 18 months of follow-up.
    Makhlough A; Shekarchian S; Moghadasali R; Einollahi B; Dastgheib M; Janbabaee G; Hosseini SE; Falah N; Abbasi F; Baharvand H; Aghdami N
    Cytotherapy; 2018 May; 20(5):660-669. PubMed ID: 29580865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single-arm pilot study of metformin in patients with autosomal dominant polycystic kidney disease.
    Sorohan BM; Ismail G; Andronesi A; Micu G; Obrișcă B; Jurubiță R; Sinescu I; Baston C
    BMC Nephrol; 2019 Jul; 20(1):276. PubMed ID: 31337351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial.
    Meijer E; Visser FW; van Aerts RMM; Blijdorp CJ; Casteleijn NF; D'Agnolo HMA; Dekker SEI; Drenth JPH; de Fijter JW; van Gastel MDA; Gevers TJ; Lantinga MA; Losekoot M; Messchendorp AL; Neijenhuis MK; Pena MJ; Peters DJM; Salih M; Soonawala D; Spithoven EM; Wetzels JF; Zietse R; Gansevoort RT;
    JAMA; 2018 Nov; 320(19):2010-2019. PubMed ID: 30422235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Yinang formulation versus placebo granules as a treatment for chronic kidney disease stages III-IV in patients with autosomal dominant polycystic kidney disease: study protocol for a double-blind placebo-controlled randomized clinical trial.
    Gan J; Wu Y; Gong X; Ma Y; Yu S; Gao J
    Trials; 2019 Aug; 20(1):481. PubMed ID: 31391092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety of autologous and metabolically fit bone marrow mesenchymal stromal cells in medically refractory Crohn's disease - a phase 1 trial with three doses.
    Dhere T; Copland I; Garcia M; Chiang KY; Chinnadurai R; Prasad M; Galipeau J; Kugathasan S
    Aliment Pharmacol Ther; 2016 Sep; 44(5):471-81. PubMed ID: 27385373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial.
    Gevers TJ; Hol JC; Monshouwer R; Dekker HM; Wetzels JF; Drenth JP
    Liver Int; 2015 May; 35(5):1607-14. PubMed ID: 25369108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cystatin C estimated glomerular filtration rate to assess renal function in early stages of autosomal dominant polycystic kidney disease.
    Sans L; Radosevic A; Quintian C; Montañés R; Gràcia S; Vilaplana C; Mojal S; Ballarin JA; Fernández-Llama P; Torra R; Pascual J
    PLoS One; 2017; 12(3):e0174583. PubMed ID: 28346513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial.
    Gansevoort RT; Hariri A; Minini P; Ahn C; Chapman AB; Horie S; Knebelmann B; Mrug M; Ong ACM; Pei YPC; Torres VE; Modur V; Antonshchuk I; Perrone RD
    Am J Kidney Dis; 2023 May; 81(5):517-527.e1. PubMed ID: 36535535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease.
    Torres VE; Devuyst O; Chapman AB; Gansevoort RT; Perrone RD; Ouyang J; Blais JD; Czerwiec FS; Sergeyeva O;
    Am J Nephrol; 2017; 45(3):257-266. PubMed ID: 28166521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomised controlled trial to determine the efficacy and safety of prescribed water intake to prevent kidney failure due to autosomal dominant polycystic kidney disease (PREVENT-ADPKD).
    Wong ATY; Mannix C; Grantham JJ; Allman-Farinelli M; Badve SV; Boudville N; Byth K; Chan J; Coulshed S; Edwards ME; Erickson BJ; Fernando M; Foster S; Haloob I; Harris DCH; Hawley CM; Hill J; Howard K; Howell M; Jiang SH; Johnson DW; Kline TL; Kumar K; Lee VW; Lonergan M; Mai J; McCloud P; Peduto A; Rangan A; Roger SD; Sud K; Torres V; Vilayur E; Rangan GK
    BMJ Open; 2018 Jan; 8(1):e018794. PubMed ID: 29358433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Preliminary Efficacy of Mesenchymal Stromal Cell (ORBCEL-M) Therapy in Diabetic Kidney Disease: A Randomized Clinical Trial (NEPHSTROM).
    Perico N; Remuzzi G; Griffin MD; Cockwell P; Maxwell AP; Casiraghi F; Rubis N; Peracchi T; Villa A; Todeschini M; Carrara F; Magee BA; Ruggenenti PL; Rota S; Cappelletti L; McInerney V; Griffin TP; Islam MN; Introna M; Pedrini O; Golay J; Finnerty AA; Smythe J; Fibbe WE; Elliman SJ; O'Brien T;
    J Am Soc Nephrol; 2023 Oct; 34(10):1733-1751. PubMed ID: 37560967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and tolerability of intradiscal implantation of combined autologous adipose-derived mesenchymal stem cells and hyaluronic acid in patients with chronic discogenic low back pain: 1-year follow-up of a phase I study.
    Kumar H; Ha DH; Lee EJ; Park JH; Shim JH; Ahn TK; Kim KT; Ropper AE; Sohn S; Kim CH; Thakor DK; Lee SH; Han IB
    Stem Cell Res Ther; 2017 Nov; 8(1):262. PubMed ID: 29141662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intra-discal injection of autologous, hypoxic cultured bone marrow-derived mesenchymal stem cells in five patients with chronic lower back pain: a long-term safety and feasibility study.
    Elabd C; Centeno CJ; Schultz JR; Lutz G; Ichim T; Silva FJ
    J Transl Med; 2016 Sep; 14(1):253. PubMed ID: 27585696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
    Torres VE; Meijer E; Bae KT; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB; Ouyang JJ; Czerwiec FS
    Am J Kidney Dis; 2011 May; 57(5):692-9. PubMed ID: 21333426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tubular secretion of creatinine in autosomal dominant polycystic kidney disease: consequences for cross-sectional and longitudinal performance of kidney function estimating equations.
    Spithoven EM; Meijer E; Boertien WE; Sinkeler SJ; Tent H; de Jong PE; Navis G; Gansevoort RT
    Am J Kidney Dis; 2013 Sep; 62(3):531-40. PubMed ID: 23714171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma metabolites and lipids associate with kidney function and kidney volume in hypertensive ADPKD patients early in the disease course.
    Kim K; Trott JF; Gao G; Chapman A; Weiss RH
    BMC Nephrol; 2019 Feb; 20(1):66. PubMed ID: 30803434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial.
    Gansevoort RT; Meijer E; Chapman AB; Czerwiec FS; Devuyst O; Grantham JJ; Higashihara E; Krasa HB; Ouyang J; Perrone RD; Torres VE;
    Nephrol Dial Transplant; 2016 Nov; 31(11):1887-1894. PubMed ID: 26681730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin Therapy in Autosomal Dominant Polycystic Kidney Disease: A Feasibility Study.
    Brosnahan GM; Wang W; Gitomer B; Struemph T; George D; You Z; Nowak KL; Klawitter J; Chonchol MB
    Am J Kidney Dis; 2022 Apr; 79(4):518-526. PubMed ID: 34391872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Copeptin levels and kidney function in ADPKD: case-control study.
    Corradi V; Martino F; Gastaldon F; Scalzotto E; Caprara C; Fortunato A; Pinaffo G; Marchetti C; Fabbi F; Giavarina D; Ferrari F; Rosner MH; Ronco C
    Clin Nephrol; 2016 Sep; 86(9):147-53. PubMed ID: 27487355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.